Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
A phase 2 trial of Mifamurtide in Osteosarcoma, run by UNICANCER, active and no longer recruiting.
Overview
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients is a phase 2 interventional study registered as NCT03643133 by UNICANCER, with 60 participants planned, started 2018-10-23 and due to reach its primary completion in 2026-09. Interventions recorded: Mifamurtide, EI or M-API regimen depending on patient age. Conditions recorded: Osteosarcoma.
Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
- TrialEvaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
- TrialLu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Shares Osteosarcoma and the tag pipeline.
- TrialCombination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
Shares Osteosarcoma and the tag pipeline.
- TrialStudy to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Shares Osteosarcoma and the tag pipeline.
- TrialHigh Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
Shares Osteosarcoma and the tag pipeline.
- TrialWill Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Shares Osteosarcoma and the tag pipeline.
- TrialDepsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Shares Osteosarcoma and the tag pipeline.